| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Stock-based compensation expense | - | 3,662 |
| Net loss | - | -55,463 |
| Prepaid expenses and other current assets | - | -4,818 |
| Other assets | - | -35 |
| Accrued expenses | - | 479 |
| Accounts payable | - | 1,722 |
| Depreciation expense | - | 175 |
| Amortization of premium on marketable securities | - | -1,216 |
| Lease expense | - | -133 |
| Net cash used in operating activities | - | -45,921 |
| Maturities of marketable securities | - | 113,500 |
| Purchases of property and equipment | - | 68 |
| Purchases of marketable securities | - | 80,142 |
| Net cash provided by (used in) investing activities | - | 33,290 |
| Net cash provided by financing activities | - | 0 |
| Net increase in cash, cash equivalents and restricted cash | 56,922 | -12,631 |
| Cash and cash equivalents at beginning of period | 33,824 | - |
| Cash and cash equivalents at end of period | 90,746 | - |
Larimar Therapeutics, Inc. (LRMR)
Larimar Therapeutics, Inc. (LRMR)